The lack of EGFR mutations in CRC and supra-additive toxicity of EGFR TKI to chemotherapy regimens may partly explain why development of EGFR TKI in advanced CRC would be unlikely to be fruitful. Here, EGFR is linked to colorectal carcinoma.